Three-year follow-up from CheckMate 017/057: Nivolumab versus docetaxel in patients with previously treated advanced non-small cell lung cancer (NSCLC)

被引：0

作者：

Felip Font, E. ^{[1
]}

Gettinger, S. N. ^{[2
]}

Burgio, M. A. ^{[3
]}

Antonia, S. J. ^{[4
]}

Holgado, E. ^{[5
]}

Spigel, D. R. ^{[6
]}

Arrieta, O. ^{[7
]}

Domine Gomez, M. ^{[8
]}

Aren Frontera, O. ^{[9
]}

Brahmer, J. ^{[10
]}

Chow, L. Q. ^{[11
]}

Crino, L. ^{[12
]}

Butts, C. ^{[13
]}

Coudert, B. ^{[14
]}

Horn, L. ^{[15
]}

Steins, M. ^{[16
]}

Geese, W. J. ^{[17
]}

Li, A. ^{[17
]}

Healey, D. ^{[17
]}

Vokes, E. E. ^{[18
]}

机构：

[1] Hosp Univ Vall dHebron, Thorac Tumors Grp, Barcelona, Spain

[2] Yale Canc Ctr, Oncol, New Haven, CT 06510 USA

[3] IRCCS Ist Sci Romagnolo Studio & Cura Tumori, Oncol, Meldola, Italy

[4] H Lee Moffitt Canc Ctr & Res Inst, Oncol, Tampa, FL USA

[5] Hosp Madrid, Oncol, Norte Sanchinarro, Madrid, Spain

[6] Tennessee Oncol PLLC, Sarah Cannon Res Inst, Med Oncol, Nashville, TN 37203 USA

[7] Inst Nacl Cancerol, Oncol, Mexico City, DF, Mexico

[8] Fdn Jimenez Diaz, Oncol, Madrid, Spain

[9] Ctr Int Estudios Clin, Oncol, Santiago, Chile

[10] Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Oncol, Baltimore, MD 21231 USA

[11] Univ Washington, Oncol, Seattle, WA 98195 USA

[12] Osped Perugia, Oncol, Perugia, Italy

[13] Cross Canc Inst, Oncol, Edmonton, AB, Canada

[14] Ctr Georges Francois Leclerc, Oncol, Dijon, France

[15] Vanderbilt Ingram Canc Ctr, Thorac Oncol, Nashville, TN 37232 USA

[16] Heidelberg Univ Hosp, Thoraxklin, Oncol, Heidelberg, Germany

[17] Bristol Myers Squibb, Immunooncol, Princeton, NJ 08540 USA

[18] Univ Chicago Med & Biol Sci, Oncol, Chicago, IL 60637 USA

来源：

ANNALS OF ONCOLOGY | 2017年 / 28卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1301PD

引用

页数：1

共 50 条

[21] Phase III, randomized trial (CheckMate 057) of nivolumab (NIVO) versus docetaxel (DOC) in advanced non-squamous cell (non-SQ) non-small cell lung cancer (NSCLC)
Paz-Ares, Luis
Horn, Leora
Borghaei, Hossein
Spigel, David R.
Steins, Martin
Ready, Neal
Chow, Laura Quan Man
Vokes, Everett E.
Felip, Enriqueta
Holgado, Esther
Barlesi, Fabrice
Kohlhaeufl, Martin
Rodriguez, Oscar
Burgio, Marco Angelo
Fayette, Jerome
Gettinger, Scott N.
Harbison, Christopher
Dorange, Cecile
Finckenstein, Friedrich Graf
Brahmer, Julie R.
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (18)
[22] Impact of baseline serum cytokines on survival in patients (pts) with advanced squamous (SO) non-small cell lung cancer (NSCLC) treated with nivolumab (nivo) or docetaxel (doc): Exploratory analyses from CheckMate 063 and CheckMate 017
Farsaci, Benedetto
Geese, William J.
Desai, Kaushal D.
Jin, Chelsea
Antonia, Scott J.
Lena, Herve
Horn, Leora
Planchard, David
Reckamp, Karen L.
Stinchcombe, Thomas E.
Gettinger, Scott
Borghaei, Hossein
Hellmann, Matthew D.
Harbison, Christopher
Xu, Dong
Blackwood-Chirchir, M. Anne
Rizvi, Naiyer
CANCER RESEARCH, 2016, 76
[23] Evaluation of health-related quality of life and symptoms in patients with advanced non-squamous non-small cell lung cancer treated with nivolumab or docetaxel in CheckMate 057
Reck, Martin
Brahmer, Julie
Bennett, Bryan
Taylor, Fiona
Penrod, John R.
DeRosa, Michael
Dastani, Homa
Spigel, David R.
Gralla, Richard J.
EUROPEAN JOURNAL OF CANCER, 2018, 102 : 23 - 30
[24] Estimated costs of managing treatment-related adverse events (TRAEs) of nivolumab (nivo) and docetaxel (doc) in the CheckMate 017 and CheckMate 057 phase III non-small cell lung cancer (NSCLC) trials
Venkatachalam, Meena
Stenehjem, David D.
Pietri, Guilhem
Penrod, John R.
Korytowsky, Beata
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[25] SAPPHIRE: Phase III study of sitravatinib plus nivolumab versus docetaxel in patients with previously treated advanced non-squamous non-small cell lung cancer (NSCLC)
Borghaei, H.
Johnson, M. L.
Garon, E. B.
He, K.
Planchard, D.
Reck, M.
Popat, S.
Herbst, R. S.
Leal, T. A.
Dumoulin, D.
De Marinis, F.
Reynolds, C. H.
Theelen, W. S. M. E.
Percent, I.
Calderon, V. Gutierrez
Flandin, A. C. Madroszyk
Shazer, R. L.
Yan, X.
Harrigan, R.
Peters, S.
ANNALS OF ONCOLOGY, 2023, 34 : S1308 - S1308
[26] Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer (NSCLC)
Rogado, J.
Pacheco-Barcia, V.
Fenor De la Maza, M. D.
Serra, J. M.
Toquero, P.
Vera, B.
Obispo, B.
Mondejar, R.
Ballesteros, A.
Donnay, O.
Colomer, R.
Sanchez-Torres, J. M.
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1915 - S1916
[27] Nivolumab Versus Docetaxel for Previously Treated Advanced Non-Small Cell Lung Cancer in China: A Cost-Effectiveness Analysis
Qiao Liu
Xia Luo
Liubao Peng
Lidan Yi
Xiaomin Wan
Xiaohui Zeng
Chongqing Tan
Clinical Drug Investigation, 2020, 40 : 129 - 137
[28] Nivolumab Versus Docetaxel for Previously Treated Advanced Non-Small Cell Lung Cancer in China: A Cost-Effectiveness Analysis
Liu, Qiao
Luo, Xia
Peng, Liubao
Yi, Lidan
Wan, Xiaomin
Zeng, Xiaohui
Tan, Chongqing
CLINICAL DRUG INVESTIGATION, 2020, 40 (02) : 129 - 137
[29] Long-term outcomes with nivolumab in patients with previously treated advanced Non-Small Cell Lung Cancer (NSCLC)
Thomas, M.
Kohlhaeufl, M.
Reck, M.
Engel-Riedel, W.
Kortsik, C.
Bullinger, L.
Schneider, C. -P.
Felip, E.
Brahmer, J.
Vokes, E.
Gettinger, S.
Geese, W.
Yoon, D.
Healey, D.
Li, A.
Eberhardt, W. E. E.
ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 : 137 - 137
[30] Impact of of Nivolumab versus Docetaxel on Health-Related Quality of Life and Symptoms in Patients with Advanced Squamous Non-Small Cell Lung Cancer: Results from the CheckMate 017 Study
Reck, Martin
Taylor, Fiona
Penrod, John R.
DeRosa, Michael
Morrissey, Laura
Dastani, Homa
Orsini, Lucinda
Gralla, Richard J.
JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (02) : 194 - 204

← 1 2 3 4 5 →